Basic Information
Qinlock
Regulatory Information
EMEA/H/C/005614
November 18, 2021
September 16, 2021
6
October 11, 2024
Company Information
the netherlands
Atrium Building Floor 4th Strawinskylaan 3051 1077 ZX Amsterdam
Deciphera Pharmaceuticals (Netherlands) Bv
Drug Classification
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib.
Overview Summary
Qinlock is a cancer medicine used to treat gastrointestinal stromal tumour (GIST), a cancer of the stomach and bowel, in adults with advanced disease who have already been treated with three or more medicines of the ‘kinase inhibitor’ class, including a medicine called imatinib. GIST is rare, and Qinlock was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 12 October 2017. Qinlock contains the active substance ripretinib.